Recently the biologic HUMIRA (adalimumab) was approved by the FDA for the treatment of moderate to severe hidradenitis supparativa (HS), an often debilitating disease with inflammatory papules, cysts and sinuses in the groin, axilla, inframammary and buttocks areas. This is an exciting new addition to the armamentarium of treatments, which typically include topical and oral antibiotics, as well as surgical approaches. In two clinical studies, PIONEER I and PIONEER II, it was demonstrated that at 12 weeks, patients with moderate-to-severe HS treated with HUMIRA achieved a statistically significant greater response compared to those on placebo on the Hidradenitis Suppurativa Clinical Response (HiSCR) measure.
